Chuanhuizi Chen

Title: **Innovative Contributions of Chuanhuizi Chen in Pharmaceutical Research**

Introduction

Chuanhuizi Chen is a distinguished inventor located in Shanghai, China. He has made significant strides in the field of pharmaceutical research, contributing to advancements in drug development. With 1 patent to his name, Chen stands out as an innovative thinker in medicinal chemistry.

Latest Patents

Chen's noteworthy patent, titled "Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors," showcases his creativity and expertise. This invention describes a piperazinotriazole compound represented by general formula I, including its pharmaceutically acceptable salts, stereoisomers, tautomers, or hydrates. The patent also encompasses a pharmaceutical composition that utilizes this compound, along with methods for preparing the compound and using it as a highly selective inhibitor of poly(adenosine diphosphate-ribose) polymerase-1 (PARP-1). The implications of this invention are vast, particularly for the prevention and treatment of PARP-related diseases.

Career Highlights

Chuanhuizi Chen is affiliated with the Shanghai Institute of Materia Medica, part of the esteemed Chinese Academy of Sciences. His role at this renowned research institution has allowed him to engage in critical studies that enhance the understanding and treatment of various diseases through innovative pharmacological approaches.

Collaborations

Throughout his career, Chen has collaborated with esteemed colleagues, including Ao Zhang and Zehong Miao. These partnerships have fostered a productive research environment, leading to significant breakthroughs in medicinal chemistry and pharmaceutical innovations.

Conclusion

Chuanhuizi Chen exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the development of PARP-1 inhibitors, highlight his role in addressing critical health challenges. As he continues his research at the Shanghai Institute of Materia Medica, we can anticipate further advancements and discoveries that may significantly impact the field of drug development.